United Statesfujifilmbiotechnologies.fujifilm.com
Its role Owner
FUJIFILM Biotechnologies is a leading contract development and manufacturing organization (CDMO) that provides end-to-end services for the development and commercial production of biologics, vaccines, and advanced therapies. It specializes in cell line development, process and analytical development, and large-scale cGMP manufacturing using microbial, mammalian, and host/virus expression systems.
The company operates a global network of facilities with major sites in the United States, the United Kingdom, and Denmark. Its flagship U.S. site in Holly Springs, North Carolina, is one of North America’s largest commercial-scale cell culture biomanufacturing facilities, featuring eight 20,000-liter bioreactors for drug substance production along with co-located drug product capabilities. Phase two expansion will double capacity with an additional eight bioreactors.
As a subsidiary of FUJIFILM Corporation (itself part of FUJIFILM Holdings Corporation headquartered in Tokyo, Japan), FUJIFILM Biotechnologies benefits from the parent group’s resources while maintaining operational independence in its CDMO activities. It employs over 5,000 people worldwide and follows the kojoX network philosophy to ensure consistency and efficiency across sites.
The company positions itself as a trusted partner in the biopharmaceutical industry, supporting clients from preclinical stages through to commercial supply of complex biologic medicines. Its Holly Springs operations, announced with significant investments exceeding $3 billion, underscore its role in expanding U.S. biomanufacturing capacity.
Also known as FUJIFILM Diosynth Biotechnologies.
chemXplore tracks 2 projects involving Fujifilm Biotechnologies, of which one is active.
Besides this one, the record holds 1 completed project.
Closest to start-up first.
The 1 that is completed, on hold or cancelled are in the record. See all 2 in chemXplore →
active all projects
